China-based Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced on Wednesday positive preliminary results from its Phase IIa clinical trial of ISM001-055.
ISM001-055 is a first-in-class small molecule aimed at TNIK (Traf2- and Nck-interacting kinase) and was designed using generative AI to treat idiopathic pulmonary fibrosis (IPF). The primary and the secondary efficacy endpoints of the study have been met, demonstrating dose-dependent response in forced vital capacity (FVC), a critical measure of lung function in IPF patients.
The company's proprietary AI platform facilitated ISM001-055's target identification and molecular design. The Phase IIa study was a randomised, double-blind, placebo-controlled trial that enrolled 71 patients with IPF across 21 sites in China. Patients were randomised to receive either placebo, 30mg once daily (QD), 30mg twice daily (BID) or 60mg QD for a period of 12 weeks.
Complete topline data will be released at an upcoming medical conference and clinical trial results will be submitted for publication in a peer-reviewed journal.
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024